XNAS · Healthcare · Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.25 | -0.26 | -4.00% | $2.8M | ❌ Miss | -2.33% | -3.62% | — |
| 2026-03-09 | Q4 2025 | -0.24 | -0.06 | +75.00% | $24.7M | ✅ Beat | -2.50% | +9.48% | +18.97% |
| 2025-11-10 |
| Q3 2025 |
| -0.38 |
| -0.28 |
| +26.32% |
| $7.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.39 | -0.63 | -61.54% | $3.6M | ❌ Miss | -0.44% | +14.85% | +18.34% |
| 2025-05-12 | Q1 2025 | -0.59 | -0.43 | +27.12% | $4.7M | ✅ Beat | — | — | — |
| 2025-03-05 | Q4 2024 | -0.38 | -0.40 | -5.26% | $30.6M | ❌ Miss | — | — | — |
| 2024-11-04 | Q3 2024 | -0.78 | -0.75 | +3.85% | $61,000 | ✅ Beat | — | — | — |
| 2024-08-07 | Q2 2024 | -0.70 | -0.82 | -17.14% | $513,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.